Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Diagnosis

Methods used in the diagnosis of hematological malignancies are constantly evolving, with novel technologies being developed, and an increased importance being placed on earlier diagnosis, patient risk stratification, and genomic testing. Discover the latest in the field in several disease areas, including multiple myeloma, CLL, AML, ALL, and lymphoma.

Multiple Myeloma

View all
Addressing unmet needs in multiple myeloma: a preview of the MYELOMAS meeting 1:42
Addressing unmet needs in multiple myeloma: a preview of the MYELOMAS meeting
Claudio Cerchione • 13 Oct 2026
Insights into what to expect at the 2026 MYELOMAS meeting 2:09
Insights into what to expect at the 2026 MYELOMAS meeting
Claudio Cerchione • 13 Oct 2026

CLL

View all
Value of genomic assessment in guiding first-line CLL treatment: FISH, IGHV, and TP53 testing 1:27
Value of genomic assessment in guiding first-line CLL treatment: FISH, IGHV, and TP53 testing
Nitin Jain • 1 Oct 2026
Integrating molecular testing into frontline treatment decisions in CLL 2:11
Integrating molecular testing into frontline treatment decisions in CLL
Kerry Rogers • 10 Sep 2026

AML

View all
Differentiation syndrome in menin inhibitor-treated patients: recognition, management & next steps 6:18
Differentiation syndrome in menin inhibitor-treated patients: recognition, management & next steps
Eunice Wang et al. • 18 Sep 2026
Combining differentiation therapy with BCL2 inhibition: impact on the DS risk profile 0:39
Combining differentiation therapy with BCL2 inhibition: impact on the DS risk profile
Stéphane de Botton • 18 Sep 2026

ALL

View all
Updated genomic insights in Ph+ acute lymphoblastic leukemia 5:12
Updated genomic insights in Ph+ acute lymphoblastic leukemia
Ilaria Iacobucci • 12 Jun 2026
Insights into emerging treatment options for Ph+ ALL: TKI and immunotherapy combinations 1:26
Insights into emerging treatment options for Ph+ ALL: TKI and immunotherapy combinations
Ilaria Iacobucci • 12 Jun 2026

Lymphoma

View all
Single-cell and proteomic data to predict ibrutinib response in Waldenström macroglobulinemia 1:33
Single-cell and proteomic data to predict ibrutinib response in Waldenström macroglobulinemia
Tina Bagratuni • 23 Sep 2026
CTCs and plasma MYD88 VAF as liquid biopsy markers in Waldenström macroglobulinemia 1:52
CTCs and plasma MYD88 VAF as liquid biopsy markers in Waldenström macroglobulinemia
Tina Bagratuni • 23 Sep 2026

Non-Malignant

View all
When to suspect and test for paroxysmal nocturnal hemoglobinuria 1:00
When to suspect and test for paroxysmal nocturnal hemoglobinuria
Yasutaka Ueda • 13 Jun 2026
Incidence & management of TA-TMA in settings with limited access to biomarkers and targeted therapy 2:38
Incidence & management of TA-TMA in settings with limited access to biomarkers and targeted therapy
Nour Ben Abdeljelil • 23 Mar 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals